DOMANTIS LIMITED
Company number 03907643 · Monitor this company
Executive summary
Domantis Limited is a mature, structurally robust pharmaceutical R&D subsidiary wholly owned and controlled by Glaxo Group Limited (GSK). While its standalone financial metrics are shielded from public view due to its audit-exempt subsidiary status, it exhibits no symptoms of distress and maintains perfect regulatory compliance. Its financial health is intrinsically tied to the strength of its parent company, operating securely within GSK's broader corporate immune system.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2000-01-17
- Registered office
- Gsk Medicines Research Centre, Gunnels Wood Road, Stevenage, United Kingdom, SG1 2NY
- Postcode
- SG1 2NY
- Capital
- 6,875 GBP
- Accounts category
- Audit Exemption Subsidiary
- Charges
- 0 outstanding
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2026-09-10
- Next due by
- 2027-09-24
Nature of business (SIC)
- 72190 Other research and experimental development on natural sciences and engineering
Officers 4 current · 27 resigned
Group structure
Controlled by GLAXO GROUP LIMITED — since 2016-04-06
From persons-with-significant-control filings on the public register.
Previous company names
| Name | Date changed |
|---|---|
| DIVERSYS LIMITED | 2002-04-29 |
| MELLOWGIFT LIMITED | 2000-06-21 |
Previous registered addresses 5
| Address | Changed on |
|---|---|
| 315 CAMBRIDGE SCIENCE PARK, CAMBRIDGE, CAMBRIDGESHIRE, CB4 0WG | 2007-01-18 |
| GRANTA PARK, ABINGTON, CAMBRIDGE, CB1 6GS | 2004-01-10 |
| 20 PARK CRESCENT, LONDON, W1N 4AL | 2001-12-17 |
| 90 LONG ACRE, LONDON, WC2E 9TT | 2000-04-21 |
| 120 EAST ROAD, LONDON, N1 6AA | 2000-03-23 |
Among its peers
Among the oldest 25%
of 53 similar companies in SG, trading since 2000
The class of 2000
41%
of the 75,534 companies incorporated in 2000 are still active today; 56% have since been dissolved.
A fact about the year, not a forecast for this company.